Gennaro Pagano, MD, MSc, PhD, Roche Pharma Research & Early Development, Basel, Switzerland, discusses the multifaceted nature of Parkinson’s disease and the various factors contributing to its development and progression. While alpha-synuclein is recognized as a key driver of the disease, inflammation and dysfunctional lysosomes also play a role. Targeting all these factors simultaneously could potentially help prevent the disease. Additionally, direct targeting of microglia, which are activated by aggregated proteins and neuronal loss, is being explored as a strategy. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Dr Pagano is a full-time employee and shareholder at F. Hoffmann – La Roche Ldt.